Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.'s, Lemonaid Health is able to offer the fast-acting ED medication at improved pricing. With one in 10 men estimated to have ED at some point in their lifetime, Lemonaid Health clinicians are able to evaluate and prescribe patients a variety of ED medications at various price points and doses. Lemonaid Health services patients across the United States, and has treated over 200,000 ED patients to date.

It provides access to medication delivery from a 50 state licensed pharmacy, which has the potential to help millions of men discreetly and legally obtain a treatment for a still significantly undertreated condition. important Safety Information about STENDRA®? (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction.

STENDRA is not for use in women or children. It is not known if STENDRA is safe and effective in women or children under 18 years of age. CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, erythromycin) increase STENDRA exposure.

Combination with Other PDE5 Inhibitors or Erectile Dysfunction Therapies is not recommended. The safety of STENDRA is unknown in patients with bleeding disorders and patients with active peptic ulceration. The use of STENDRA offers no protection against sexually transmitted diseases including HIV.

Consider counseling patients on protective measures for sexually transmitted diseases. The most common adverse reactions reported with use of STENDRA include headache, flushing, nasal congestion, nasalngitis, and back pain.